Atossa Therapeutics advances Z-Endoxifen with orphan designations

Atossa Therapeutics says its (Z)-Endoxifen program received Rare Pediatric Disease and Orphan Drug designations for MAS and DMD, completed EVANGELINE Phase 2 enrollment after dosing ~800 patients, and expects IND clearances in H2 2026.